Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Study Summary

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

Conditions

Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Interventions / Drugs

Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pemetrexed, docetaxel, paclitaxel Atezolizumab Palbociclib MVASI® (bevacizumab-awwb)TNO155 IV Chemotherapy (Regimen 1)IV Chemotherapy (Regimen 2)BI 1701963 AMG 404 Everolimus

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment610 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157669+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.